Lv61
1810 积分 2024-12-27 加入
Cold to Hot: Tumor Immunotherapy by Promoting Vascular Normalization Based on PDGFB Nanocomposites
22天前
已完结
Sorafenib sensitization in tumor therapy by iron overload and AMPK activation
22天前
已完结
Hypoxia-Preconditioned Adipose Stem Cell Exosomes Promote Adipose Graft Vascular Regeneration via miRNA-126
22天前
已完结
Advancements in immunotherapy for gastric cancer: Unveiling the potential of immune checkpoint inhibitors and emerging strategies
22天前
已完结
Diagnostic Value of a Global Leadership Initiative on Malnutrition Criteria in Patients with Malignant Tumors: A Systematic Review and Meta-Analysis
23天前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
6个月前
已完结
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
6个月前
已完结
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
6个月前
已完结
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
6个月前
已完结
Pioneering precision: The evolution of immunotherapy for hepatocellular carcinoma
6个月前
已完结
皖公网安备34019202002308
